BIOPHARM
2025–2026 federal contribution records · FEC Schedule A
01
Contribution summary
Loading the financial summary…
Reading the shared contribution publication for this cycle.
2025–2026 federal contribution records · FEC Schedule A
Loading the financial summary…
Reading the shared contribution publication for this cycle.
Federal contribution records grouped across normalized variants of this reported employer. Contributions are made by individuals, not by the employer.
Current-version rows · memo entries excluded from net amount
Last updated .
Loading 10 contributions with dates…
Loading company overview…
These immutable labels appeared in FEC filings and are grouped under BIOPHARM.
Top 10 contributors and top 10 recipients · independent of list pagination
Explore the reported connections for Biopharm. Contributor and recipient lists are available below.
Data: GovMoneyGraph, based on FEC records. Groupings and recipient-party allocations are derived analysis, not FEC-verified identities or party registrations. Read our contribution and classification methodology.
Reported contributor groups, with evidence-based name-variant matching; not verified unique people · 10 per page
Showing 1–2 of 2 · largest absolute amount first
Reported name + ZIP cluster; not a verified identity merge · ALPINE, UT, 84004 · BIOPHARM · EMPLOYEE · 137 transaction rows
RepublicanDerived from contributionsEvidence-based cluster of 2 reported identities; not a verified identity merge · ENCINITAS, CA, 92024 · BIOPHARM · CONSULTANT · Reported as FUJIKAWA, ELLEN / FUJIKAWA, ELLEN K · 15 transaction rows
DemocraticDerived from contributionsWhere the contributions went · 10 per page
Showing 1–3 of 3 · largest absolute amount first
Party committee (qualified) · WASHINGTON, DC · 127 transaction rows
RepublicanDerived from contributionsHybrid PAC (qualified) · WASHINGTON, DC · 15 transaction rows
DemocraticDerived from contributionsPAC with non-contribution account · CHEYENNE, WY · 10 transaction rows
RepublicanDerived from contributionsIndividual transactions · 10 per page
Dates below are the FEC-reported contribution dates, not filing or import dates. These are individual contributions grouped by the reported employer field, not contributions by a company.
Largest contribution amounts first. Select Date of contribution or Amount to reverse the order.
| Date of contribution ↕ | Amount ↓ | Reported contributor / location | Recipient / filing |
|---|---|---|---|
| 2025-06-09FEC filing ↗ | $20 | IRWIN, BEVERLYALPINEUT84004EMPLOYEEBIOPHARM | NRCCC00075820Primary (P)EARMARKED FROM WINREDFiling 1943491 · amended |
| 2025-03-09FEC filing ↗ | $20 | IRWIN, BEVERLYALPINEUT84004EMPLOYEEBIOPHARM | NRCCC00075820Primary (P)EARMARKED FROM WINREDFiling 1889655 |
| 2025-03-15FEC filing ↗ | $20 | FUJIKAWA, ELLENENCINITASCA92024CONSULTANTBIOPHARM | HMPC00495028Primary (P)* EARMARKED CONTRIBUTION: SEE BELOWFiling 1909696 |
| 2025-04-09FEC filing ↗ | $20 | IRWIN, BEVERLYALPINEUT84004EMPLOYEEBIOPHARM | NRCCC00075820Primary (P)EARMARKED FROM WINREDFiling 1893573 |
| 2025-05-09FEC filing ↗ | $20 | IRWIN, BEVERLYALPINEUT84004EMPLOYEEBIOPHARM | NRCCC00075820Primary (P)EARMARKED FROM WINREDFiling 1896906 |
| 2025-01-09FEC filing ↗ | $20 | IRWIN, BEVERLYALPINEUT84004EMPLOYEEBIOPHARM | NRCCC00075820Primary (P)EARMARKED FROM WINREDFiling 1878165 |
| 2025-02-09FEC filing ↗ | $20 | IRWIN, BEVERLYALPINEUT84004EMPLOYEEBIOPHARM | NRCCC00075820Primary (P)EARMARKED FROM WINREDFiling 1882098 |
| 2025-06-16FEC filing ↗ | $16 | FUJIKAWA, ELLENENCINITASCA92024CONSULTANTBIOPHARM | HMPC00495028Primary (P)* EARMARKED CONTRIBUTION: SEE BELOWFiling 1909696 |
| 2025-03-16FEC filing ↗ | $16 | FUJIKAWA, ELLENENCINITASCA92024CONSULTANTBIOPHARM | HMPC00495028Primary (P)* EARMARKED CONTRIBUTION: SEE BELOWFiling 1909696 |
| 2025-03-30FEC filing ↗ | $16 | FUJIKAWA, ELLENENCINITASCA92024CONSULTANTBIOPHARM | HMPC00495028Primary (P)* EARMARKED CONTRIBUTION: SEE BELOWFiling 1909696 |
Refunds remain negative. Memo-only rows are marked and are not additional money. Rows come from the latest available contribution publication.
Open full contribution table →